United States Patent 5,466,446: Claim Scope, Expiration, Orange Book Status, and Benzoyl Peroxide-Clindamycin Patent Landscape

U.S. Patent No. 5,466,446 protected a topical gel combining benzoyl peroxide and clindamycin in a defined pharmaceutical carrier. Its independent claims covered both the composition and the method of applying it to skin disorders involving sebaceous glands and follicles. The patent issued on November 14, 1995, and its enforceable term was based on the pre-1995 17-year patent term, resulting in expiration in November 2012, subject to any applicable adjustments or terminal disclaimers. The patent is therefore expired and cannot presently block generic manufacture, sale, or use in the United States.

The patent was directed to the formulation used in the BenzaClin product family, although commercial products generally expressed the antibiotic as clindamycin phosphate rather than unmodified clindamycin. The patent’s strongest historical protection was the combination of active ingredients with a narrowly described gel vehicle and a minimum three-month ambient-temperature stability requirement.

What does U.S. Patent 5,466,446 cover?

U.S. Patent 5,466,446 covers a topical gel containing:

Component	Claimed amount or requirement
Benzoyl peroxide	At least 4.5% by weight
Clindamycin	At least 0.9% by weight
Disodium monolauryl sulfosuccinate	About 0.04%
Carbomer	About 2.0%
Disodium EDTA	About 0.1%
Dimethicone	About 0.1%
Hydrated silica	About 0.25%
Poloxamer 182	About 0.20%
Sodium hydroxide	About 0.31%
Physical form	Topical gel
Stability	At least three months at ambient temperature
Therapeutic use	Skin disorders involving sebaceous glands and follicles

The patent has two independent claims.

Claim 1 is a composition claim. It requires a topical gel containing the specified benzoyl peroxide and clindamycin concentrations, together with a carrier consisting essentially of the listed excipients, and requires stability for at least three months at ambient temperature.

Claim 2 is a method claim. It requires topically applying the claimed benzoyl peroxide-clindamycin gel to affected human skin to treat disorders involving sebaceous glands and follicles.

The use of “consisting essentially of” is central to claim interpretation. It permits components that do not materially alter the basic and novel characteristics of the claimed composition, while potentially excluding additional ingredients that materially affect the formulation’s stability, delivery, or therapeutic characteristics.

How narrow are the claims of Patent 5,466,446?

The claims are narrow because they combine active-ingredient thresholds, a defined excipient system, a gel dosage form, a stability limitation, and a therapeutic-use limitation.

Active-ingredient limitations

A competing formulation must contain at least 4.5% benzoyl peroxide and at least 0.9% clindamycin to fall within the express concentration limitations. A product containing 5% benzoyl peroxide and 1% clindamycin would meet those numerical thresholds, assuming the clindamycin concentration is measured on the same basis used by the patent.

The clindamycin basis matters. Commercial products often contain clindamycin phosphate equivalent to approximately 1% clindamycin. A product label that states “clindamycin phosphate 1%” does not automatically resolve whether the patent claim’s “clindamycin” limitation is met. The analysis depends on the patent specification, claim construction, and whether the salt is treated as the claimed active form or as an equivalent.

Carrier limitations

The carrier limitation substantially reduces the claim’s breadth. The claimed formulation is not any benzoyl peroxide-clindamycin gel. It is a gel containing a specified group of excipients in approximately specified amounts.

A product can avoid literal infringement by changing one or more excipients, materially altering their concentrations, or using a different stabilizing and rheology system. The legal outcome would depend on the meaning of “about,” the role of the altered ingredient, and the doctrine of equivalents.

Stability limitation

The three-month ambient-temperature stability requirement is a limitation, not merely a product characteristic. The patent owner would need to show that the accused composition satisfies the stability requirement. Conversely, an accused manufacturer could challenge the limitation through formulation data showing that its product does not remain stable for the required period under the relevant conditions.

The stability requirement also gives the patent technical significance. Benzoyl peroxide and clindamycin can present formulation compatibility and degradation issues. The claimed excipient combination was intended to maintain product performance in a single ready-to-use gel.

Method-of-use limitation

Claim 2 is limited to treating skin disorders involving sebaceous glands and follicles in humans. The language is consistent with acne treatment, but it is not drafted as a general claim to treating every dermatological condition.

The method claim requires topical application of a gel containing the specified active ingredients and carrier. It does not cover oral, injectable, transdermal, or otherwise non-topical administration.

What products were associated with Patent 5,466,446?

The patent is historically associated with BenzaClin, a topical acne product containing benzoyl peroxide and clindamycin phosphate. The FDA-approved BenzaClin formulation contained benzoyl peroxide and clindamycin phosphate in a topical gel vehicle. FDA labeling identified the product for the treatment of acne vulgaris in patients 12 years and older, subject to the applicable labeling version.[2]

The commercial formulation and the patent claims are related but not necessarily identical in every drafting detail. Patent protection must be assessed against the precise formulation, active-ingredient expression, manufacturing process, and approved labeling. A product’s association with a patent does not establish that every commercial presentation satisfies every claim limitation.

When did Patent 5,466,446 lose exclusivity?

Patent 5,466,446 expired in November 2012 based on the 17-year term applicable to patents issuing from applications filed before the transition to the 20-year patent term.[1] The patent issued November 14, 1995, making November 14, 2012, the apparent term-ending date under the standard issue-date calculation.

Event	Date or status
U.S. patent application	Filed before the 1995 patent-term transition
Patent issued	November 14, 1995
Patent term basis	Generally 17 years from issue
Expected expiration	November 14, 2012
Current status	Expired
Current blocking effect	None, absent an unusual surviving right or separate patent

Patent expiration ended the enforceable exclusionary rights under the patent. It did not invalidate historical infringement claims that accrued before expiration, subject to applicable limitation periods and litigation requirements.

What was the Orange Book status of Patent 5,466,446?

Patent 5,466,446 was listed in the FDA Orange Book in connection with the BenzaClin product family, according to historical FDA-approved drug patent listings.[3] The listing provided an FDA regulatory mechanism for identifying patent certifications associated with abbreviated new drug applications.

An Orange Book listing does not itself determine patent validity, enforceability, or infringement. It identifies patents submitted by the new drug application holder or sponsor as relevant to the listed drug.

The key regulatory consequences were:

An ANDA applicant seeking approval of a generic benzoyl peroxide-clindamycin product had to address each listed patent.
A Paragraph IV certification could assert that the patent was invalid, unenforceable, or would not be infringed.
A timely patent-infringement suit could trigger a 30-month FDA approval stay under the Hatch-Waxman framework.
Once the patent expired, the listed patent no longer created a continuing patent-based approval barrier.

FDA Orange Book records should be separated from current approved-label information. A patent may remain visible in historical regulatory records after its expiration, but it no longer supplies an operative exclusivity period.

Which companies challenged the BenzaClin patent estate?

The historical generic challenge environment included ANDA applicants seeking approval for clindamycin phosphate and benzoyl peroxide topical products. Public FDA records and historical patent litigation reports associate generic competition with companies including Perrigo and Actavis, although the exact party, ANDA number, asserted claims, and resolution must be evaluated from the specific docket and FDA correspondence.[3][4]

The principal Hatch-Waxman risk was a Paragraph IV challenge to Patent 5,466,446. The challenge would have focused on one or more of the following issues:

Whether the accused product contained the claimed excipient system.
Whether clindamycin phosphate satisfied the clindamycin limitation.
Whether the excipient concentrations fell within the meaning of “about.”
Whether the formulation met the three-month stability requirement.
Whether the claims were obvious over earlier benzoyl peroxide, clindamycin, acne-gel, and stability disclosures.
Whether the patent was enforceable in view of prosecution conduct or disclosure issues.

Because the patent expired in 2012, any 30-month stay associated with a pre-expiration Paragraph IV suit could not extend the patent’s substantive exclusionary term. Generic entry after expiration was not blocked by Patent 5,466,446.

What settlement agreements affected generic entry?

The existence and commercial effect of any settlement must be analyzed separately from patent expiration. A Hatch-Waxman settlement can establish a contractual launch date, license, or other commercial restriction, but it cannot extend the patent’s legal term beyond expiration.

For Patent 5,466,446, the decisive commercial event was expiration in 2012. Any settlement that permitted entry before expiration would have had historical relevance. After expiration, the patent itself did not support a continuing restriction on generic launch.

A complete settlement analysis would require the agreement, court docket, FTC review materials, or contemporaneous FDA records. The patent record alone does not establish the full economic terms of a confidential or partially redacted settlement.

How strong was the patent estate for benzoyl peroxide and clindamycin gel?

Patent 5,466,446 had moderate historical strength as a product-specific formulation patent but limited breadth as a platform patent.

Strengths

It claimed the active combination used in a recognized acne product.
It included a defined gel vehicle rather than only the active ingredients.
It required stability, a technically relevant property for the combination.
It included both composition and method-of-use claims.
The concentration thresholds aligned with commercially relevant benzoyl peroxide-clindamycin products.

Weaknesses

The carrier was unusually detailed and could be designed around.
The claim used “about” for excipient concentrations, creating claim-construction issues.
The patent did not broadly cover every topical combination of benzoyl peroxide and clindamycin.
The patent’s therapeutic-use language was limited to disorders involving sebaceous glands and follicles.
The patent expired more than a decade ago.
Later products could rely on different vehicles, preservatives, packaging systems, or separate active-ingredient presentations.

The patent was therefore more valuable as a barrier to copying the specific formulation than as a barrier to the entire therapeutic category.

What formulation patents followed Patent 5,466,446?

The post-1995 patent landscape for topical acne products expanded beyond the specific carrier in Patent 5,466,446. Relevant patent categories included:

Patent category	Typical subject matter	Commercial purpose
Combination formulations	Benzoyl peroxide with clindamycin or another antibiotic	Single-product acne treatment
Stabilized gels	Reduced degradation or improved active compatibility	Longer shelf life
Aqueous or anhydrous vehicles	Alternative solvent and water systems	Formulation flexibility
Packaging systems	Dual-chamber or separated-active systems	Prevent premature interaction
Microsphere and encapsulation systems	Controlled release or reduced irritation	Improved tolerability
Method-of-use patents	Specific acne populations or dosing regimens	Regulatory and commercial differentiation
Manufacturing patents	Mixing, particle-size control, or activation methods	Process protection

These later patents could have created separate barriers even after Patent 5,466,446 expired. A freedom-to-operate review must therefore examine the current assignee’s entire U.S. portfolio, issued patents, pending applications, continuations, and relevant Orange Book listings.

Did Patent 5,466,446 create biosimilar risk?

No. Biosimilar law does not apply to benzoyl peroxide or clindamycin because both are small-molecule active ingredients. Competitive risk arose through generic-drug pathways, primarily ANDAs under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The principal regulatory issues were sameness, formulation equivalence, inactive ingredients, topical-product performance, labeling, and patent certifications. A biosimilar application under the Public Health Service Act was not the relevant route.

What generic launch scenarios existed?

The main launch scenarios were:

Scenario	Commercial result
Paragraph III certification	Approval delayed until patent expiration
Paragraph IV certification without successful injunction	Approval could occur after the statutory stay or litigation resolution
Paragraph IV litigation settlement	Entry governed by settlement terms
Non-infringing formulation	Potential approval without infringing the listed claims
Post-expiration ANDA approval	Patent 5,466,446 no longer blocks launch

Generic manufacturers could also avoid the patent by using a different gel carrier, changing the excipient system, separating the active ingredients, or developing an alternative dosage form. Those approaches would still require FDA approval and would need separate evaluation under other active patents.

What geographic coverage did Patent 5,466,446 have?

The patent provided rights only in the United States. It did not directly protect the formulation in Canada, Europe, Japan, or other markets.

International protection would have depended on corresponding national applications and granted patents. Patent families can differ materially by country because of prosecution amendments, claim scope, term adjustments, oppositions, invalidity proceedings, and national filing dates.

For U.S. commercial planning, the expired status of Patent 5,466,446 removes this patent as a current U.S. barrier. It does not establish freedom to operate in foreign markets.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers may remain even after patent expiration. A generic manufacturer must demonstrate reproducible control of:

Benzoyl peroxide particle size and dispersion.
Clindamycin or clindamycin phosphate assay and uniformity.
Gel viscosity and spreadability.
pH and preservative performance.
Active degradation and impurity formation.
Container compatibility.
Microbial quality.
Stability through the proposed shelf life.

These technical requirements do not recreate patent exclusivity. They affect development cost, approval timing, batch-release risk, and product quality.

Separate manufacturing-process patents, packaging patents, trademarks, trade secrets, and regulatory exclusivities may also affect market entry. BenzaClin branding and trade dress are distinct from the expired patent and require separate trademark and unfair-competition analysis.

How does Patent 5,466,446 compare with broader acne-product patents?

Patent 5,466,446 is narrower than a claim directed simply to “a topical composition comprising benzoyl peroxide and clindamycin.” Its carrier and stability limitations reduce its literal scope.

It is broader than a claim limited to one exact commercial batch formula because it uses “about” for several excipient concentrations and claims a composition class meeting the listed structural and functional requirements.

Its practical value depended on how closely a generic product copied the original vehicle. A generic using the same active concentrations but a substantially different carrier would present a materially different infringement analysis from a generic duplicating the full excipient system.

Key Takeaways

U.S. Patent 5,466,446 claimed a topical benzoyl peroxide-clindamycin gel and a method of treating sebaceous-gland and follicular disorders.
The claims required at least 4.5% benzoyl peroxide, at least 0.9% clindamycin, a specified excipient system, gel form, and three-month ambient-temperature stability.
The patent was associated with the BenzaClin product family.
The patent’s historical scope was formulation-specific, not a broad monopoly over every benzoyl peroxide-clindamycin product.
The patent issued November 14, 1995, and expired in November 2012 under the pre-1995 17-year patent term.
It was an Orange Book-listed patent for the relevant drug product, but its expiration ended its current blocking effect.
Generic competition proceeded through the ANDA and Paragraph IV framework, not the biosimilar pathway.
Current U.S. risk must be assessed against later patents, process patents, packaging rights, trademarks, and regulatory requirements.
Patent 5,466,446 remains relevant for historical litigation and formulation analysis but does not provide present-day U.S. exclusivity.

Frequently Asked Questions

Can a generic use 5% benzoyl peroxide and 1% clindamycin after Patent 5,466,446 expired?

Yes. The expired patent no longer prevents use of those active concentrations. The manufacturer must still address other live patents, FDA requirements, and applicable trademark restrictions.

Does clindamycin phosphate automatically infringe a claim reciting clindamycin?

No. The answer depends on claim construction, the patent specification, the formulation’s active-ingredient basis, and possible equivalents analysis.

Did Patent 5,466,446 cover a clindamycin-only acne gel?

No. The independent claims require the benzoyl peroxide-clindamycin combination.

Could a formulation with different excipients avoid the patent?

Potentially. A materially different carrier may avoid literal infringement, although the patent owner could have asserted the doctrine of equivalents before expiration.

Is BenzaClin still protected by the expired patent outside the United States?

No. A U.S. patent has no direct legal effect outside the United States. Foreign protection would depend on separate national patents and their respective expiration dates.

References

United States Patent and Trademark Office. (1995). U.S. Patent No. 5,466,446: Topical compositions containing benzoyl peroxide and clindamycin.
U.S. Food and Drug Administration. (n.d.). BenzaClin clindamycin phosphate and benzoyl peroxide topical gel prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
Federal Trade Commission. (n.d.). Agreements filed under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2142530	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,466,446

Summary for Patent: 5,466,446